+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Cutaneous T-Cell Lymphoma - Pipeline Review, H2 2015

  • ID: 3446794
  • Report
  • September 2015
  • 195 pages
  • Global Markets Direct
1 of 4
Cutaneous T-Cell Lymphoma - Pipeline Review, H2 2015

Summary

The report ‘Cutaneous T-Cell Lymphoma - Pipeline Review, H2 2015’, provides an overview of the Cutaneous T-Cell Lymphoma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Cutaneous T-Cell Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cutaneous T-Cell Lymphoma and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Cutaneous T-Cell Lymphoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Cutaneous T-Cell Lymphoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Cutaneous T-Cell Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Cutaneous T-Cell Lymphoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Cutaneous T-Cell Lymphoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Cutaneous T-Cell Lymphoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 4

Loading
LOADING...

3 of 4
List of Tables

List of Figures

Introduction

REPORT COVERAGE

Cutaneous T-Cell Lymphoma Overview

Therapeutics Development

Pipeline Products for Cutaneous T-Cell Lymphoma - Overview

Pipeline Products for Cutaneous T-Cell Lymphoma - Comparative Analysis

Cutaneous T-Cell Lymphoma - Therapeutics under Development by Companies

Cutaneous T-Cell Lymphoma - Therapeutics under Investigation by Universities/Institutes

Cutaneous T-Cell Lymphoma - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Cutaneous T-Cell Lymphoma - Products under Development by Companies

Cutaneous T-Cell Lymphoma - Products under Investigation by Universities/Institutes

Cutaneous T-Cell Lymphoma - Companies Involved in Therapeutics Development

4SC AG

Affimed Therapeutics AG

Chipscreen Biosciences Ltd

Cornerstone Pharmaceuticals, Inc.

Cyclacel Pharmaceuticals, Inc.

Eisai Co., Ltd.

Galderma S.A.

Innate Pharma SA

Johnson & Johnson

Karyopharm Therapeutics, Inc.

Kyowa Hakko Kirin Co., Ltd.

MedImmune, LLC

Neumedicines Inc.

Novartis AG

OncoSec Medical Inc.

Onyx Pharmaceuticals, Inc.

Sanofi

Seattle Genetics, Inc.

Soligenix, Inc.

Taiwan Liposome Company, Ltd.

TetraLogic Pharmaceuticals

Cutaneous T-Cell Lymphoma - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

A-dmDT390-bisFv - Drug Profile

Product Description

Mechanism of Action

R&D Progress

AFM-13 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

alemtuzumab - Drug Profile

Product Description

Mechanism of Action

R&D Progress

AMP-224 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Angeloxin - Drug Profile

Product Description

Mechanism of Action

R&D Progress

bexarotene - Drug Profile

Product Description

Mechanism of Action

R&D Progress

brentuximab vedotin - Drug Profile

Product Description

Mechanism of Action

R&D Progress

carfilzomib - Drug Profile

Product Description

Mechanism of Action

R&D Progress

CIGB-128 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

CPI-613 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

CS-055 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

DNA IL-12 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

everolimus - Drug Profile

Product Description

Mechanism of Action

R&D Progress

IPH-4102 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

mogamulizumab - Drug Profile

Product Description

Mechanism of Action

R&D Progress

NMIL-121 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

quisinostat hydrochloride - Drug Profile

Product Description

Mechanism of Action

R&D Progress

resminostat - Drug Profile

Product Description

Mechanism of Action

R&D Progress

sapacitabine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

selinexor - Drug Profile

Product Description

Mechanism of Action

R&D Progress

SGX-301 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

SHP-141 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

trifarotene - Drug Profile

Product Description

Mechanism of Action

R&D Progress

vinorelbine tartrate - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Cutaneous T-Cell Lymphoma - Recent Pipeline Updates

Cutaneous T-Cell Lymphoma - Dormant Projects

Cutaneous T-Cell Lymphoma - Discontinued Products

Cutaneous T-Cell Lymphoma - Product Development Milestones

Featured News & Press Releases

Aug 04, 2015: Soligenix Receives Orphan Drug Designation from the European Commission for SGX301 as a Treatment for Cutaneous T-Cell Lymphoma

Jun 23, 2015: Soligenix Announces Collaboration with the National Organization for Rare Disorders and the Cutaneous Lymphoma Foundation in Advancing its Phase 3 Study of SGX301 for the Treatment of Cutaneous T-Cell Lymphoma

Apr 07, 2015: DSG Partners with Soligenix to Battle Cutaneous T-Cell Lymphoma

Jan 07, 2015: FDA Grants Soligenix Fast Track”Designation for SGX301 for the First-Line Treatment of Cutaneous T-Cell Lymphoma

Dec 18, 2014: TetraLogic Announces Initiation of a Randomized Phase 2 Clinical Trial of SHAPE in Subjects With Cutaneous T-Cell Lymphoma

Nov 03, 2014: IPH 4102 Preclinical Data Published In Cancer Research

Sep 17, 2014: Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma

Aug 27, 2014: Innate Pharma's IPH4102 Receives Orphan Drug Designation In European Union

Apr 08, 2014: Seattle Genetics Achieves Milestones Under Collaboration with Takeda for Achieving First Commercial Sales of ADCETRIS in Key Countries

Apr 07, 2014: OncoSec Medical To Relaunch Phase II Cutaneous T-Cell Lymphoma Study at Key Centers of Excellence

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Cutaneous T-Cell Lymphoma, H2 2015

Number of Products under Development for Cutaneous T-Cell Lymphoma - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Number of Products under Investigation by Universities/Institutes, H2 2015

Comparative Analysis by Late Stage Development, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Development, H2 2015

Products under Development by Companies, H2 2015

Products under Development by Companies, H2 2015 (Contd..1)

Products under Investigation by Universities/Institutes, H2 2015

Cutaneous T-Cell Lymphoma - Pipeline by 4SC AG, H2 2015

Cutaneous T-Cell Lymphoma - Pipeline by Affimed Therapeutics AG, H2 2015

Cutaneous T-Cell Lymphoma - Pipeline by Chipscreen Biosciences Ltd, H2 2015

Cutaneous T-Cell Lymphoma - Pipeline by Cornerstone Pharmaceuticals, Inc., H2 2015

Cutaneous T-Cell Lymphoma - Pipeline by Cyclacel Pharmaceuticals, Inc., H2 2015

Cutaneous T-Cell Lymphoma - Pipeline by Eisai Co., Ltd., H2 2015

Cutaneous T-Cell Lymphoma - Pipeline by Galderma S.A., H2 2015

Cutaneous T-Cell Lymphoma - Pipeline by Innate Pharma SA, H2 2015

Cutaneous T-Cell Lymphoma - Pipeline by Johnson & Johnson, H2 2015

Cutaneous T-Cell Lymphoma - Pipeline by Karyopharm Therapeutics, Inc., H2 2015

Cutaneous T-Cell Lymphoma - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2015

Cutaneous T-Cell Lymphoma - Pipeline by MedImmune, LLC, H2 2015

Cutaneous T-Cell Lymphoma - Pipeline by Neumedicines Inc., H2 2015

Cutaneous T-Cell Lymphoma - Pipeline by Novartis AG, H2 2015

Cutaneous T-Cell Lymphoma - Pipeline by OncoSec Medical Inc., H2 2015

Cutaneous T-Cell Lymphoma - Pipeline by Onyx Pharmaceuticals, Inc., H2 2015

Cutaneous T-Cell Lymphoma - Pipeline by Sanofi, H2 2015

Cutaneous T-Cell Lymphoma - Pipeline by Seattle Genetics, Inc., H2 2015

Cutaneous T-Cell Lymphoma - Pipeline by Soligenix, Inc., H2 2015

Cutaneous T-Cell Lymphoma - Pipeline by Taiwan Liposome Company, Ltd., H2 2015

Cutaneous T-Cell Lymphoma - Pipeline by TetraLogic Pharmaceuticals, H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Stage and Target, H2 2015

Number of Products by Stage and Mechanism of Action, H2 2015

Number of Products by Stage and Route of Administration, H2 2015

Number of Products by Stage and Molecule Type, H2 2015

Cutaneous T-Cell Lymphoma Therapeutics - Recent Pipeline Updates, H2 2015

Cutaneous T-Cell Lymphoma - Dormant Projects, H2 2015

Cutaneous T-Cell Lymphoma - Dormant Projects (Contd..1), H2 2015

Cutaneous T-Cell Lymphoma - Discontinued Products, H2 2015

List of Figures

Number of Products under Development for Cutaneous T-Cell Lymphoma, H2 2015

Number of Products under Development for Cutaneous T-Cell Lymphoma - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Top 10 Targets, H2 2015

Number of Products by Stage and Top 10 Targets, H2 2015

Number of Products by Top 10 Mechanism of Actions, H2 2015

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015

Number of Products by Top 10 Routes of Administration, H2 2015

Number of Products by Stage and Top 10 Routes of Administration, H2 2015

Number of Products by Top 10 Molecule Types, H2 2015

Number of Products by Stage and Top 10 Molecule Types, H2 2015
Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll